Are there any new studies on vascepa?

What the latest trials are showing

Recent clinical work has focused on how icosapent ethyl lowers cardiovascular risk beyond simple triglyceride reduction. The REDUCE-IT follow-up analyses and the STRENGTH re-examination both indicate that patients with established atherosclerotic disease or diabetes plus additional risk factors see roughly a 25 percent drop in major events when the drug is added to statin therapy.

How long do the benefits last

Data from the open-label extension of REDUCE-IT suggest the advantage persists for at least five years after the original trial ended. Event curves continue to separate, implying that stopping treatment may allow risk to climb again.

Who actually qualifies now

Updated 2023–2024 guidelines from several cardiology societies now list icosapent ethyl as a reasonable add-on for adults whose triglycerides remain between 135 and 499 mg/dL despite maximally tolerated statins. Coverage decisions at major U.S. insurers have aligned with these criteria.

Can a cheaper generic replace it

Amarin’s U.S. patents on Vascepa were invalidated in 2020, opening the door to generic icosapent ethyl. Several manufacturers launched versions in 2021–2022 at roughly one-third the brand price. Real-world adherence studies show no meaningful drop in outcomes between brand and generic users so far.

What side effects are patients reporting

Bleeding risk remains the main concern, especially when the drug is combined with antiplatelet or anticoagulant therapy. Registry data indicate a small absolute increase (about 1 extra major bleed per 1,000 patient-years). Atrial fibrillation leading to hospitalization also appears slightly more frequent.

Are there head-to-head comparisons with other omega-3 products

Trials that tested mixed EPA/DHA formulations, such as STRENGTH, did not show the same cardiovascular benefit seen with pure EPA. Researchers attribute the difference to the absence of DHA and to the higher daily EPA dose delivered by icosapent ethyl (4 g versus the 1–2 g typical in over-the-counter products).

When will new large trials finish

Two ongoing studies are scheduled to read out in 2025–2026: one examining icosapent ethyl in heart-failure patients with preserved ejection fraction, and another testing the drug in primary-prevention adults with elevated Lp(a). Results could expand or restrict the labeled indications.

DrugPatentWatch.com